John Lafin
University of Texas Southwestern Medical Center
H-index: 10
North America-United States
Top articles of John Lafin
Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5‐alpha reductase inhibitor resistance
The Prostate
2024/1/3
John Lafin
H-Index: 5
Qi Liu
H-Index: 28
MP01-16 MOLECULAR DRIVERS OF ORGANOTROPISM AND CISPLATIN RESISTANCE IN GERM CELL TUMORS
Journal of Urology
2024/5/1
Andrew Elliott
H-Index: 12
John Lafin
H-Index: 5
Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers
2024/3/31
Unraveling the testicular seminoma tumor microenvironment by single-cell RNA-sequencing.
2024/2/1
Refining the serum miR-371a-3p test for viable germ cell tumor detection
Scientific reports
2023/6/29
AGCT1531: Evaluating the utility of circulating microRNA in the management of children, adolescents, and adults with malignant germ cell tumors.
2023/6/1
The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors.
2023/6/1
Evaluation of miR‐371a‐3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection
Andrology
2023/5
MP33-15 COMPARISON OF SERUM miR-371a-3p ASSAY PERFORMANCE BY DIGITAL DROPLET PCR AND REVERSE TRANSCRIPTASE QUANTITATIVE PCR IN MALIGNANT GERM CELL TUMOR PATIENTS
The Journal of Urology
2023/4
MP60-14 A CELLULAR ATLAS OF THE NORMAL ADULT HUMAN FEMALE URETHRA
The Journal of Urology
2023/4
John Lafin
H-Index: 5
Douglas Strand
H-Index: 20
Management of Testicular Germ Cell Tumor With Somatic-Type Malignancy.
Oncology (Williston Park, NY)
2022/6/1
PD51-03 MOLECULAR CHARACTERISTICS OF METASTATIC TERATOMAS AND MATCHED PRIMARY TESTICULAR GERM CELL TUMORS
The Journal of Urology
2022/5
MP46-02 REFINEMENT OF THE SERUM MIR-371A-3P TEST FOR THE DETECTION OF CHEMOTHERAPY-NAIVE MINIMAL RESIDUAL TESTICULAR CANCER
The Journal of Urology
2022/5
PD51-06 EVALUATION OF MIR-371A-3P PERFORMANCE IN DETECTING SEMINOMATOUS TESTICULAR CANCER METASTASES
The Journal of Urology
2022/5
Evaluating the discriminatory capacity of miR-371A-3P in the context of pure seminomatous testicular cancer metastases.
2022/2/20
Evaluation of a risk-adapted strategy in the primary surgical management of clinical stage IIA testicular cancer.
2022/2/20
Optimization of serum miR-371a-3p for the detection of chemotherapy-naïve minimal residual germ cell tumor.
2022/2/20
Molecular analysis of primary testicular germ cell tumor and matched metastatic teratomas.
2022/2/20
Real-world application of pre-orchiectomy miR-371a-3p test in testicular germ cell tumor (GCT) management.
2021/2/20
Correction to: Germ Cell Tumor Cell Culture Techniques
Testicular Germ Cell Tumors: Methods and Protocols
2021
